0000000000228264

AUTHOR

Irina Nikishina

showing 6 related works from this author

Proceedings Of The 23Rd Paediatric Rheumatology European Society Congress: Part Two

2017

lcsh:Diseases of the musculoskeletal systemlcsh:RJ1-570lcsh:Pediatricslcsh:RC925-935Meeting Abstracts
researchProduct

INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry

2021

Contains fulltext : 231528.pdf (Publisher’s version ) (Closed access) BACKGROUND: TNF receptor-associated periodic syndrome (TRAPS) is a rare autoinflammatory disease caused by dominant mutation of the TNF super family receptor 1A (TNFRSF1A) gene. Data regarding long-term treatment outcomes are lacking. OBJECTIVE: To assess correlations of genotype-phenotypes in patients with TRAPS, as defined by the International Study Group for Systemic Autoinflammatory Diseases (INSAID) classification and Eurofever criteria, with treatment responses. METHODS: Data from 226 patients with variants of the TNFRSF1A gene and enrolled in the Eurofever registry were classified according to the INSAID classifica…

medicine.medical_specialtyAbdominal painAutoinflammatory diseasesGroup AGroup BAA amyloidosis Anakinra Autoinflammatory diseases Colchicine TRAPS Abdominal Pain Colchicine FemaleHumans Mutation Registries Hereditary Autoinflammatory Diseases03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaAA amyloidosisTNF receptor-associated periodic syndrome (TRAPS) ; TNFRSF1A geneInternal medicinemedicineAA amyloidosisHumansImmunology and AllergyIn patientRegistries030212 general & internal medicineLikely pathogenicAnakinrabusiness.industryHereditary Autoinflammatory DiseasesTRAPSmedicine.diseaseAbdominal PainAnakinra030228 respiratory systemTNF receptor associated periodic syndromeMutationFemalemedicine.symptombusinessColchicineAA amyloidosis; Anakinra; Autoinflammatory diseases; Colchicine; TRAPSInflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]medicine.drug
researchProduct

Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.

2015

Objective.The main objective was to determine the 2-year clinical benefit and safety of etanercept (ETN) in children with the juvenile idiopathic arthritis (JIA) categories of extended oligoarthritis (eoJIA), enthesitis-related arthritis (ERA), or psoriatic arthritis (PsA).Methods.CLIPPER was a 96-week, phase IIIb, open-label, multicenter study. Patients with eoJIA, ERA, or PsA received ETN 0.8 mg/kg once weekly (50 mg max) for up to 96 weeks. The proportions of patients reaching the JIA American College of Rheumatology (ACR) 30/50/70/90/100 and inactive disease responses at Week 96 were calculated. Adverse events (AE) were collected throughout the study (intention-to-treat sample).Results.…

Malemedicine.medical_specialtyAdolescentEnthesitis-related arthritisImmunologyArthritisJuvenilePsoriaticEtanerceptEtanercept03 medical and health sciencesPsoriatic arthritis0302 clinical medicineRheumatologyInternal medicinemedicineImmunology and AllergyHumans030212 general & internal medicinePreschoolChild030203 arthritis & rheumatologyOligoarthritisbusiness.industryArthritisArthritis PsoriaticClinical trial; Enthesitis-related arthritis; Etanercept; Extended oligoarthritis; Juvenile idiopathic arthritis; Psoriatic arthritis; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Arthritis Psoriatic; Child; Child Preschool; Etanercept; Female; Humans; Male; Treatment OutcomeJuvenile idiopathic arthritismedicine.diseaseRheumatologyPharyngitisArthritis Juvenile3. Good healthSurgeryClinical trialUpper respiratory tract infectionTreatment OutcomePsoriatic arthritisAntirheumatic AgentsChild PreschoolExtended oligoarthritisBronchitisFemalemedicine.symptombusinessmedicine.drugThe Journal of rheumatology
researchProduct

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis : 6-year efficac…

2019

Background To describe the 6-year safety and efficacy of etanercept (ETN) in children with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA), and psoriatic arthritis (PsA) Methods Patients who completed the 2-year, open-label, phase III CLinical Study In Pediatric Patients of Etanercept for Treatment of ERA, PsA, and Extended Oligoarthritis (CLIPPER) were allowed to enroll in its 8-year long-term extension (CLIPPER2). Children received ETN at a once-weekly dose of 0.8 mg/kg, up to a maximum dose of 50 mg/week. Efficacy assessments included the JIA core set of outcomes, the JIA American College of Rheumatology response criteria (JIA-ACR), and t…

Malelcsh:Diseases of the musculoskeletal systemArthritisCHILDRENCATEGORIESDISEASE-ACTIVITYEtanerceptEtanerceptEnthesitis-related arthritis (ERA)Juvenile Arthritis Disease Activity ScoreDOUBLE-BLINDINITIATIONNECROSIS-FACTORDEFINING CRITERIAMedicine and Health SciencesMedicineChildNon-U.S. Gov'tClinical trial; Efficacy; Enthesitis-related arthritis; Enthesitis-related arthritis (ERA); Etanercept; Extended oligoarticular juvenile idiopathic arthritis (eoJIA); Juvenile idiopathic arthritis; Psoriatic arthritis (PsA); SafetyOligoarthritisResearch Support Non-U.S. Gov'tMETHOTREXATEClinical trialTreatment OutcomeAntirheumatic AgentsChild PreschoolFemaleSafetymedicine.drugResearch Articlemedicine.medical_specialtyAdolescentEfficacyEnthesitis-related arthritisResearch SupportPsoriatic arthritisPsoriatic arthritis (PsA)Internal medicineAdalimumabJournal ArticleHumansetanercept ; juvenile idiopathic arthritis ; enthesitis-related arthritis ; extended oligoarticular juvenile idiopathic arthritis (eoJIA) ; enthesitis-related arthritis (ERA) ; psoriatic arthritis (PsA) ; efficacy ; safety ; clinical trialPEDIATRIC-PATIENTSbusiness.industryJuvenile idiopathic arthritismedicine.diseaseRheumatologyArthritis JuvenileOligoarticular Juvenile Idiopathic Arthritislcsh:RC925-935Extended oligoarticular juvenile idiopathic arthritis (eoJIA)businessADALIMUMAB
researchProduct

Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study

2019

Made available in DSpace on 2019-10-05T16:54:20Z (GMT). No. of bitstreams: 0 Previous issue date: 2019-04-01 IRCCS Istituto Giannina Gaslini Background To our knowledge, the characteristics and burden of childhood arthritis have never been studied on a worldwide basis. We aimed to investigate, with a cross-sectional study, the prevalence of disease categories, treatment methods, and disease status in patients from across different geographical areas and from countries with diverse wealth status. Methods In this multinational, cross-sectional, observational cohort study, we asked international paediatric rheumatologists from specialised centres to enrol children with a diagnosis of juvenile …

Malemedicine.medical_specialtyChildhood arthritisCross-sectional studyPopulationGlobal HealthPediatrics03 medical and health sciences0302 clinical medicine030225 pediatricsEpidemiologymedicineDevelopmental and Educational PsychologyJournal ArticleHumansPediatrics Perinatology and Child Health; Developmental and Educational Psychology030212 general & internal medicineHealthcare DisparitiesChildeducationDisease burdenPain MeasurementRetrospective Studieseducation.field_of_studyOligoarthritisbusiness.industryPerinatology and Child HealthJuvenile idiopathic arthritismedicine.diseaseJUVENILE IDIOPATHIC ARTHRITIS; OF-RHEUMATOLOGY RECOMMENDATIONS; DISEASE-ACTIVITY SCORE; DEFINING CRITERIA; CLASSIFICATION; CHILDREN; EPIDEMIOLOGY; VALIDATION; COUNTRIES; VALIDITYArthritis Juvenilechildhood arthritisphenotypic variabilityobservational cohort studyCross-Sectional StudiesBiological Variation PopulationSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAAntirheumatic AgentsChild PreschoolPediatrics Perinatology and Child HealthQuality of LifeFemalePolyarthritisJuvenile idiopatic arthritis of-rheumatology recommentadions disease-activity score defining criteria classification children epidemiology validation countries validitybusinessDemographyCohort study
researchProduct

Additional file 1: of Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arth…

2019

Table S1. Summary of missing data imputation methods for the responder analysis. Table S2. Disease activity and patient-reported outcomes (observed cases). Table S3. Outcomes specific for enthesitis-related arthritis and psoriatic arthritis (observed cases). Table S4. The most frequent TEAEs, excluding infections and injection site reactions (> 5% in any JIA subtype, by System Organ Class). Figure S1. ACR30–100 and JIA inactive disease response rates (OC vs NRI). Additional Tables (A1 to A4) and Figure A1 related to missing data imputation based on patients’ enrolment status, trial period at cut-off date, and reasons for permanent discontinuation. (DOCX 224 kb)

researchProduct